Patents Assigned to Pharma Pass
-
Patent number: 9139815Abstract: The invention relates to stems cells derived from bone marrow, and uses thereof in tissue regeneration.Type: GrantFiled: May 1, 2007Date of Patent: September 22, 2015Assignee: Pharma Pass II LLCInventors: Cornelis H. Kleinbloesem, Paul Giles
-
Publication number: 20140220123Abstract: A process for the manufacture of compositions containing niacin, the process including a first compaction step of niacin or a pharmaceutically acceptable salt thereof, then a second compaction step of a dry blend comprising niacin and microcrystalline cellulose and a further compression step into tablets. Stable tablet compositions including niacin are capable of extended release of niacin.Type: ApplicationFiled: February 1, 2013Publication date: August 7, 2014Applicant: PHARMA PASS II LLCInventors: Benoit Schmitt, Laurent Imler
-
Publication number: 20140087059Abstract: The manufacture of compositions containing montelukast and to stable tablet compositions resulting thereof are disclosed, which include a first compaction step of a dry blend including, montelukast or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, and a further compression step into tablets.Type: ApplicationFiled: September 21, 2012Publication date: March 27, 2014Applicant: PHARMA PASS LLCInventors: Benoit Schmitt, Laurent Imler
-
Publication number: 20090227682Abstract: The invention provides a xetine or salt thereof composition having a dissolution in a phosphate buffer at pH 6.8, using USP basket 10 Mesh at 75 rpm, of at least 15% at 60 minutes, of at least 40% at 120 minutes, of at least 70% at 300 minutes.Type: ApplicationFiled: March 4, 2008Publication date: September 10, 2009Applicant: Pharma PASS II LLCInventors: Benoit Schmitt, Laurent Imler
-
Publication number: 20090226515Abstract: The present invention relates to an improved statin or salt thereof composition, especially an atorvastatin composition, which exhibits enhanced dissolution properties in acidic media. It comprises a statin active ingredient and an aminoalkyl methacrylate copolymer dispersed therein, such as dimethyl aminoethyl methacrylate. The invention also relates to a process for preparing the improved composition and to methods of using it for the treatment of dyslipidemia.Type: ApplicationFiled: March 4, 2008Publication date: September 10, 2009Applicant: Pharma PASS II LLCInventors: Benoit Schmitt, Laurent Imler
-
Publication number: 20090226516Abstract: The invention provides a sartan or salt thereof composition having a dissolution in acetate buffer at pH 4.Type: ApplicationFiled: March 4, 2008Publication date: September 10, 2009Applicant: Pharma PASS II LLCInventors: Benoit Schmitt, Laurent Imler
-
Patent number: 6368628Abstract: The invention provides a sustained release composition free of food effect comprising a core comprising an active agent except for carbamazepine or verapamil, and a coating comprising, based on the weight of the coating, from 30 to 80% of a gastroresistant polymer and from 10 to 40% of a hydrophilic silicon dioxide. The invention also provides a method of alleviating food effect in a pharmaceutical composition. The invention also provides a dispersion useful thereof.Type: GrantFiled: May 26, 2000Date of Patent: April 9, 2002Assignee: Pharma Pass LLCInventor: Pawan Seth
-
Patent number: 6350471Abstract: The invention provides a delayed release tablet, comprising: (i) a core comprising an active ingredient selected from the group consisting of oxybutynin hydrochloride, propranolol hydrochloride, buspiron hydrochloride, niacin, cetirizin hydrochloride, cerivastin sodium, metoprolol fumarate, and alendronate sodium., and conventional excipients; and (ii) a coating consisting essentially of a water-insoluble, water-permeable film- forming polymer, a plasticizer and a water-soluble polymer.Type: GrantFiled: May 31, 2000Date of Patent: February 26, 2002Assignee: Pharma Pass LLCInventor: Pawan Seth
-
Patent number: 6348469Abstract: The invention provides a solid composition comprising glipizide which is not in an amorphous form; polyethylene oxide; the balance consisting of conventional additives; and a functional coating; exhibiting a dissolution profile such that after 4 hours, from 10 to 30% of the glipizide is released, after 8 hours, from 40 to 60% of the glipizide is released, after 12 hours, from 80 to 100% of the glipizide is released.Type: GrantFiled: May 26, 2000Date of Patent: February 19, 2002Assignee: Pharma Pass LLCInventor: Pawan Seth
-
Patent number: 6338857Abstract: The invention provides a sustained release composition free of food effect comprising: (c) a core comprising carbamazepine; and (d) a functional coating comprising, based on the weight of the coating, from 30 to 80% of a gastroresistant polymer and from 10 to 40% of a hydrophilic silicon dioxide. The invention also provides a method for alleviating food effect in a carbamazepine pharmaceutical composition.Type: GrantFiled: May 26, 2000Date of Patent: January 15, 2002Assignee: Pharma Pass LLCInventor: Pawan Seth
-
Patent number: 6159499Abstract: The present invention relates to a composition, particularly adapted to oral administration, substantially free of alkaline-reacting compounds. The composition comprises (a) a core containing an acid-labile benzimidazole active principle, where the core comprises a plurality of nuclei and the active principle mixed together and then compressed together, and where the active principle is not in the form of an alkaline salt; (b) an intermediate layer; and (c) an enteric layer; provided that omeprazole is not the benzimidazole active principle. A process for preparing the composition is also disclosed.Type: GrantFiled: October 20, 1998Date of Patent: December 12, 2000Assignee: Pharma Pass LLCInventor: Pawan Seth
-
Patent number: 6143327Abstract: The invention provides a delayed release coated tablet, free of stabilizer and free of pore-forming agent comprising: (i) a core consisting essentially of bupropion hydrochloride, a binder and a lubricant; and (ii) a first coating consisting essentially of a water-insoluble, water-permeable film-forming polymer, a plasticizer and a water-soluble polymer; and (iii) a second coating consisting essentially of a methacrylic polymer and a plasticizer therefor.Type: GrantFiled: December 13, 1999Date of Patent: November 7, 2000Assignee: Pharma Pass LLCInventor: Pawan Seth
-
Patent number: 6117453Abstract: A solid composition is disclosed comprising an active ingredient that is not in amorphous form in association with polyethylene oxide and conventional additives, excluding basic compounds. Such compositions are suitable for use as pharmaceutical compositions. A method for their preparation is also disclosed.Type: GrantFiled: October 14, 1997Date of Patent: September 12, 2000Assignee: Pharma PassInventors: Pawan Seth, Andre Stamm
-
Patent number: 6096341Abstract: The invention provides a controlled release tablet, free of stabilizer and free of pore-forming agent comprising: (i) a core consisting essentially of bupropion hydrochloride, a binder and a lubricant; and (ii) a coating consisting essentially of a water-insoluble, water-permeable film-forming polymer, a plasticizer and a water-soluble polymer.Type: GrantFiled: October 30, 1998Date of Patent: August 1, 2000Assignee: Pharma Pass LLCInventor: Pawan Seth
-
Patent number: 6033686Abstract: The invention provides a controlled release tablet, free of stabilizer and free of pore-forming agent comprising: (i) a core consisting essentially of bupropion hydrochloride, a binder and a lubricant; and (ii) a coating consisting essentially of a water-insoluble, water-permeable film-forming polymer, a plasticizer and a water-soluble polymer.Type: GrantFiled: October 30, 1998Date of Patent: March 7, 2000Assignee: Pharma Pass LLCInventor: Pawan Seth
-
Patent number: 5824341Abstract: A composition that ensures selective release of an active ingredient at a given site, and in particular, a pharmaceutical composition enabling selective release of an active ingredient to be obtained at a target organ. The composition is intended for oral administration, providing selective release of its active ingredient in the colon.Type: GrantFiled: April 22, 1997Date of Patent: October 20, 1998Assignee: Pharma PassInventors: Pawan Seth, Andre Stamm